Therapeutic Targets Database
BIDD Pharmainformatics Databases
 
   
   

 

TTD Drug ID: DAP000016

Drug Information
NameNorepinephrine
Synonyms(-)-NORADRENALINE; 1,2-Benzenediol, 4-((1R)-2-amino-1-hydroxyethyl)-; noradrenaline; LT4; PDSP2_001095; 66197-73-7; Norepinephrinum [INN-Latin]; Noradrenalina [Italian]; L-Norepinephrine; HMS2089E18; (R)-Norepinephrine; 1,2-Benzenediol, 4-[(1R)-2-amino-1-hydroxyethyl]-; Norepinephrine Noradrenalin; (R)-4-(2-Amino-1-hydroxyethyl)-1,2-benzenediol; NCGC00159406-04; HMS500L12; NCGC00159406-03; LS-42676; Noradrenalin; Levarterenol; norepinephrine; norepinefrina; SPBio_001048; CID439260; Sympathin E; (-)-(R)-Norepinephrine; L-3,4-dihydroxyphenylethanolamine; Levarterenolo [DCIT]; A7257_SIGMA; AC1L96ZT; Adrenor; Norepirenamine; KBio2_004057; KBio2_006625; LT03330026; Spectrum5_001068; 4-[(1R)-2-Amino-1-hydroxyethyl]-1,2-benzenediol; L-Noradrenaline; Noradrenalina; KBioSS_001489; 1,2-Benzenediol, 4-(2-amino-1-hydroxyethyl)-, (R)-; l-2-Amino-1-(3,4-dihydroxyphenyl)ethanol; Norepinephrine (INN); DB00368; EINECS 200-096-6; (R)-Noradrenaline; to_000024; Noradrenaline (JP15); Aktamin; (-)-Arterenol free base; SGCUT00123; BRN 4231961; Noradrenalin, l-; HMS1920B08; 4899-05-2; Noreinefrina; Norepinephrine [INN:JAN]; DivK1c_000230; Levoarterenol; CHEBI:18357; ALBB-006229; NCGC00159406-06; 1,2-Benzenediol, 4-(2-amino-1-hydroxyethyl)-, (R)- (9CI); 51-41-2; Arterenol; Nor adrenalin (TN); KBio2_001489; nchembio705-1; BSPBio_002079; nchembio.284-comp2; Levonor; Spectrum_001009; NCGC00159406-05; Norepinephrine l-Tartrate (1:1); nchembio.64-comp2; NCGC00159406-09; (-)-Norepinephrine; Levophed; (-)-Arterenol; STK503776; Benzyl alcohol, alpha-(aminomethyl)-3,4-dihydroxy-, (-)-; Spectrum2_001064; 1,2-Benzenediol, 4-((R)-2-amino-1-hydroxyethyl)-; 4-[(1R)-2-amino-1-hydroxyethyl]benzene-1,2-diol; CHEMBL1437; 51-40-1 (l-tartrate (1:1)); Levonoradrenaline; norepinephrinum; KBioGR_000635; (R)-(-)-Norepinephrine; Noradrenalinum; UNII-X4W3ENH1CV; Levarterenolo; NINDS_000230; Levonorepinephrine; KBio3_001579; Spectrum3_000520; D-(-)-Noradrenaline; NCGC00159406-07; (-)-alpha-(Aminomethyl)protocatechuyl alcohol; l-1-(3,4-Dihydroxyphenyl)-2-aminoethanol; bmse000404; KBio1_000230; HMS2091J08; L-alpha-(aminomethyl)-3,4-dihydroxybenzyl alcohol; Spectrum4_000078; NCGC00159406-02; 1,2-Benzenediol, 4-(2-amino-1-hydroxyethyl)-, (R)-(-)-; C00547; IDI1_000230; Noreinefrina [INN-Spanish]; D53D5E3A-2360-4CA9-8031-6C2CD4062FD5; Nor adrenalin; SPECTRUM1500436; PDSP1_001111; D00076; L-arterenol
CompanyBedford Laboratories
IndicationSeptic shock and neurogenic shock
[ICD9: 785, 785.52   ICD10: R57.8, R65.21]
Approved    [1]
Structure

Click to save drug structure in 3D MOL format

Click to save drug structure in 2D MOL format
InChI1S/C8H11NO3/c9-4-8(12)5-1-2-6(10)7(11)3-5/h1-3,8,10-12H,4,9H2/t8-
/m0/s1
InChIKeySFLSHLFXELFNJZ-QMMMGPOBSA-N
Canonical SMILESC1=CC(=C(C=C1C(CN)O)O)O    
Isomeric SMILESC1=CC(=C(C=C1[C@H](CN)O)O)O
Therapeutic ClassVasoconstrictor Agents
CAS NumberCAS 51-41-2
FormulaC8H11NO3
PubChem Compound IDCID 439260.
PubChem Substance IDSID 3828.
ChEBI18357;
SuperDrug ATC IDC01CA03
SuperDrug CAS ID000051412;
TargetBeta adrenergic receptorStimulator[2]
Ref 1FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 040455 To Reference
Ref 2Impact of exogenous beta-adrenergic receptor stimulation on hepatosplanchnic oxygen kinetics and metabolic activity in septic shock. Crit Care Med. 1999 Feb;27(2):325-31. To Reference



 

Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.


Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore


All rights reserved.

   
 
 
Computer-aided Drug Design
about BIDD |  databases |  software |  teaching |  research |  links

 

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543